ILMN vs RVTY vs TECH Stock Comparison

Illumina, Revvity and Bio-Techne Prices as of Oct 28, 2026 Peers: Industry group
1 more company in this comparison (DHR) Create a free account to keep reading and compare up to 10 companies.
ILMN Illumina, Inc.
$288.79 +6.2% 1M +195.3% 1Y
Market cap
$44.01B
P/E
53.3x
Revenue (TTM)
$4.49B
Div. yield
–
Life Sciences Tools Healthcare
6 wins
RVTY Revvity, Inc.
$165.36 +9.5% 1M +71.4% 1Y
Market cap
$18.62B
P/E
78.4x
Revenue (TTM)
$2.91B
Div. yield
0.00%
Life Sciences Tools Healthcare
3 wins
TECH BIO-TECHNE Corp
$72.69 +0.2% 1M +13.7% 1Y
Market cap
$11.33B
P/E
62.3x
Revenue (TTM)
$1.22B
Div. yield
0.00%
Life Sciences Tools Healthcare
3 wins

Head to Head

12 decided of 12

Illumina leads on 6 of the 12 questions below (Illumina 6, Revvity 3, Bio-Techne 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionILMNRVTYTECHLeader
Larger companyMarket capitalisation $44.01B $18.62B $11.33B ILMN
Cheaper on earningsLower P/E, profitable companies only 53.3x 78.4x 62.3x ILMN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 57.9x 32.4x 33.7x RVTY
Faster revenue growthRevenue growth, trailing twelve months +4.9% +4.1% -0.4% ILMN
More profitableNet margin, trailing twelve months 18.4% 8.2% 15.0% ILMN
Better return on capitalReturn on invested capital 15.1% 3.1% 8.3% ILMN
Less leveragedLower net debt / EBITDA 0.7x 2.8x -0.2x TECH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% TECH
Better 1-year returnPrice return, last 12 months +195.3% +71.4% +13.7% ILMN
Better 5-year returnAnnualised price return, 5 years -6.5%/yr -1.3%/yr -11.1%/yr RVTY
Less volatileAnnualised volatility, 1 year 50.4% 39.9% 43.5% RVTY
Higher overall scoreMean of the five percentile scores vs peers 65/100 58/100 66/100 TECH

Percentile Scorecard

ILMNRVTYTECH

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisILMNRVTYTECH
Valuation 50 #115 of 227 68 #74 of 227 59 #94 of 227
Growth 46 #119 of 219 28 #158 of 219 40 #131 of 219
Profitability 97 #8 of 205 80 #41 of 205 94 #14 of 205
Financial Health 51 #116 of 237 47 #127 of 237 87 #32 of 237
Shareholder Returns 83 #24 of 135 66 #46 of 135 52 #66 of 135
Overall 65 58 66
  • ILMN ranked among 247 companies in Medical Devices and Diagnostics
  • RVTY ranked among 247 companies in Medical Devices and Diagnostics
  • TECH ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodILMNRVTYTECHSPY
1 month +6.2%+9.5%+0.2% +0.9%
3 months +48.2%+45.8%+0.9% +5.9%
6 months +139.9%+101.0%+39.9% +8.5%
Year to date +120.2%+70.9%+23.6% +13.3%
1 year +195.3%+71.4%+13.7% +12.4%
3 years +171.8%+69.0%+22.1% +88.1%
3 years, per year +39.6%+19.1%+6.9% +23.5%
5 years -28.5%-6.5%-44.5% +68.2%
5 years, per year -6.5%-1.3%-11.1% +11.0%
10 years +114.2%+225.5%+187.8% +263.4%
10 years, per year +7.9%+12.5%+11.2% +13.8%

Risk

MeasureILMNRVTYTECHSPY
Volatility, 1Y 50.4%39.9%43.5% 12.7%
Downside volatility, 1Y 39.0%35.9%43.6% 12.7%
Beta vs S&P 500, 1Y 0.831.230.77 1.00
Return / volatility, 1Y 3.881.790.31 0.98
Max drawdown, 5Y -82.9%-59.2%-67.0% -25.4%
From 52-week high -1.7%0.0%0.0% -0.9%
52-week high $293.69$165.36$72.69 $779.14
52-week low $95.03$82.26$43.30 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleILMNRVTYTECH
P/E now vs peer median 52.9xmedian 28.8x 77.7xmedian 28.8x 62.3xmedian 28.8x
P/S now vs peer median 9.7xmedian 3.0x 6.3xmedian 3.0x 9.3xmedian 3.0x
EV/EBITDA now vs peer median 38.5xmedian 17.4x 26.6xmedian 17.4x 32.3xmedian 17.4x
P/FCF now vs peer median 46.8xmedian 25.7x 32.4xmedian 25.7x 43.1xmedian 25.7x
P/B now vs peer median 15.4xmedian 2.4x 2.6xmedian 2.4x 5.4xmedian 2.4x
PEG now vs peer median 1.75median 1.03 -2.49median 1.03 -4.77median 1.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsILMNRVTYTECH
Revenue $4.49B $2.91B $1.22B
Gross profit $2.98B $1.60B $799.07M
Operating income $882.00M $358.85M $251.89M
Net income $825.00M $237.55M $181.86M
Free cash flow $931.00M $568.85M $263.22M
R&D $960.00M $215.83M $94.77M
EPS (diluted) $5.39 $2.13 $1.16
Cash & equivalents $1.04B $1.02B $264.71M
Total debt $1.99B $3.21B $200.00M
Shares (diluted) 153.00M 111.63M 157.01M
Enterprise value $38.77B $14.88B $10.54B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricILMNRVTYTECH
P/E 52.9x 77.7x 62.3x
P/FCF 46.8x 32.4x 43.1x
P/Operating cash flow 39.8x 28.9x 38.8x
P/S 9.7x 6.3x 9.3x
P/B 15.4x 2.6x 5.4x
P/Tangible book 18.0x 3.7x 6.3x
EV/EBITDA 38.5x 26.6x 32.3x
EV/EBIT 50.4x 57.5x 44.8x
EV/Revenue 9.9x 7.1x 9.3x
EV/FCF 47.7x 36.3x 42.9x
EV/Operating cash flow 40.6x 32.3x 38.6x
PEG (3Y EPS CAGR) 1.75 -2.49 -4.77

Growth

14 metrics
MetricILMNRVTYTECH
Revenue growth (1Y) 4.9% 4.1% -0.4%
Revenue CAGR (3Y) -1.0% 0.9% 2.2%
Gross profit growth (1Y) 4.6% 2.3% 1.1%
Gross profit CAGR (3Y) 2.9% -0.4% 1.3%
Operating income growth (1Y) -31.8% -5.5% 146.3%
Operating income CAGR (3Y) 28.3% -3.7% -5.5%
Net income growth (1Y) -34.4% -16.7% 147.8%
Net income CAGR (3Y) 30.0% -33.8% -14.0%
EPS growth (1Y) -32.7% -12.3% 152.0%
EPS CAGR (3Y) 30.1% -31.2% -13.1%
Operating cash flow growth (1Y) -5.1% 6.2% 1.6%
Operating cash flow CAGR (3Y) 38.1% 86.9% 4.7%
Free cash flow growth (1Y) -9.7% 9.5% 2.6%
Free cash flow CAGR (3Y) 105.0% 64.8% 6.8%

Profitability

14 metrics
MetricILMNRVTYTECH
Gross margin 66.4% 55.0% 65.8%
EBITDA margin 25.7% 26.6% 28.7%
Operating margin 19.6% 12.3% 20.7%
Pretax margin 22.6% 9.0% 19.8%
Net margin 18.4% 8.2% 15.0%
FCF margin 20.7% 19.5% 21.7%
Operating cash flow margin 24.4% 21.9% 24.0%
Return on equity 29.9% 3.3% 8.7%
Return on assets 12.5% 2.0% 7.1%
Return on invested capital 15.1% 3.1% 8.3%
Return on capital employed 17.5% 3.3% 10.5%
Asset turnover 0.7x 0.2x 0.5x
Cash conversion (OCF / net income) 1.3x 2.7x 1.6x
Stock comp / revenue 5.9% 0.8% 0.5%

Financial Health

11 metrics
MetricILMNRVTYTECH
Debt / assets 29.9% 26.6% 7.7%
Debt / equity 0.7x 0.4x 0.1x
Net debt / EBITDA 0.7x 2.8x -0.2x
Debt / FCF 2.1x 5.6x 0.8x
Liabilities / assets 57.3% 40.0% 18.5%
Equity / assets 42.7% 60.0% 81.5%
Interest coverage 8.9x 3.7x 26.2x
Current ratio 1.8x 1.8x 4.5x
Quick ratio 1.2x 1.4x 2.9x
Cash ratio 0.7x 0.8x 1.6x
Altman Z-score 8.19 3.45 15.91

Shareholder Returns

7 metrics
MetricILMNRVTYTECH
Dividend yield – 0.2% 0.4%
Net buyback yield 1.2% 2.5% -0.3%
Shareholder yield 1.2% 2.7% 0.1%
Payout ratio (earnings) – 13.4% 27.4%
Payout ratio (FCF) – 5.6% 19.0%
Dividend growth (1Y) – -6.3% -0.9%
Dividend CAGR (3Y) – -6.1% -0.2%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusILMNRVTYTECH
Forward P/E 57.9xFY2026 32.4xFY2026 33.7xFY2027
EPS, next fiscal year $4.99FY2026 $5.10FY2026 $2.16FY2027
EPS growth, next FY +3.1%FY2026 +0.8%FY2026 +11.9%FY2027
EPS growth, the year after +25.7% +11.0% +5.1%
Revenue, next fiscal year $4.52BFY2026 $2.98BFY2026 $1.19BFY2027
Revenue growth, next FY +4.1%FY2026 +4.0%FY2026 -2.1%FY2027
Revenue growth, the year after +12.0% -2.0% +13.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersILMNRVTYTECH
Held by institutions 100.0% 100.0% 100.0%
Institutions holding 933 545 597
Change in shares held, QoQ +0.0% -1.3% -0.6%
Institutions buying 463 301 293
Institutions selling 330 161 241
Buyers to sellers 1.40 1.87 1.22

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ILMNRVTYTECH
ILMN 1.00 0.51 0.22
RVTY 0.51 1.00 0.45
TECH 0.22 0.45 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ILMN, RVTY and TECH?

Illumina (ILMN) is the largest by market capitalisation: Illumina (ILMN) $44.01B, Revvity (RVTY) $18.62B, Bio-Techne (TECH) $11.33B.

Which stock is cheaper, ILMN, RVTY and TECH?

Illumina (ILMN) trades on the lowest price-to-earnings ratio (Illumina (ILMN) 53.3x, Revvity (RVTY) 78.4x, Bio-Techne (TECH) 62.3x). On next year's consensus earnings, Revvity (RVTY) is cheapest (Illumina (ILMN) 57.9x, Revvity (RVTY) 32.4x, Bio-Techne (TECH) 33.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Illumina (ILMN) grew revenue fastest over the trailing twelve months: Illumina (ILMN) +4.9%, Revvity (RVTY) +4.1%, Bio-Techne (TECH) -0.4%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Illumina (ILMN) 18.4%, Revvity (RVTY) 8.2%, Bio-Techne (TECH) 15.0%). On return on invested capital, Illumina (ILMN) leads (Illumina (ILMN) 15.1%, Revvity (RVTY) 3.1%, Bio-Techne (TECH) 8.3%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Illumina (ILMN) +195.3%, Revvity (RVTY) +71.4%, Bio-Techne (TECH) +13.7%. Over five years, Revvity (RVTY) compounded fastest (Illumina (ILMN) -6.5%/yr, Revvity (RVTY) -1.3%/yr, Bio-Techne (TECH) -11.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Bio-Techne (TECH) has the highest dividend yield: Illumina (ILMN) 0.00%, Revvity (RVTY) 0.00%, Bio-Techne (TECH) 0.00%. Illumina (ILMN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Revvity (RVTY) has been the steadiest (Illumina (ILMN) 50.4%, Revvity (RVTY) 39.9%, Bio-Techne (TECH) 43.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ILMN, RVTY and TECH?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Illumina (ILMN) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.